485 related articles for article (PubMed ID: 15671549)
21. A novel telomere structure in a human alternative lengthening of telomeres cell line.
Marciniak RA; Cavazos D; Montellano R; Chen Q; Guarente L; Johnson FB
Cancer Res; 2005 Apr; 65(7):2730-7. PubMed ID: 15805272
[TBL] [Abstract][Full Text] [Related]
22. PML induces compaction, TRF2 depletion and DNA damage signaling at telomeres and promotes their alternative lengthening.
Osterwald S; Deeg KI; Chung I; Parisotto D; Wörz S; Rohr K; Erfle H; Rippe K
J Cell Sci; 2015 May; 128(10):1887-900. PubMed ID: 25908860
[TBL] [Abstract][Full Text] [Related]
23. Different telomere maintenance mechanisms in alveolar and embryonal rhabdomyosarcoma.
Ohali A; Avigad S; Naumov I; Goshen Y; Ash S; Yaniv I
Genes Chromosomes Cancer; 2008 Nov; 47(11):965-70. PubMed ID: 18663749
[TBL] [Abstract][Full Text] [Related]
24. Telomerase suppresses formation of ALT-associated single-stranded telomeric C-circles.
Plantinga MJ; Pascarelli KM; Merkel AS; Lazar AJ; von Mehren M; Lev D; Broccoli D
Mol Cancer Res; 2013 Jun; 11(6):557-67. PubMed ID: 23505069
[TBL] [Abstract][Full Text] [Related]
25. Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres.
Onitake Y; Hiyama E; Kamei N; Yamaoka H; Sueda T; Hiyama K
J Pediatr Surg; 2009 Dec; 44(12):2258-66. PubMed ID: 20006006
[TBL] [Abstract][Full Text] [Related]
26. A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT.
Cerone MA; Autexier C; Londoño-Vallejo JA; Bacchetti S
Oncogene; 2005 Nov; 24(53):7893-901. PubMed ID: 16116482
[TBL] [Abstract][Full Text] [Related]
27. Immortalized cells with no detectable telomerase activity. A review.
Reddel RR; Bryan TM; Murnane JP
Biochemistry (Mosc); 1997 Nov; 62(11):1254-62. PubMed ID: 9467849
[TBL] [Abstract][Full Text] [Related]
28. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body.
Yeager TR; Neumann AA; Englezou A; Huschtscha LI; Noble JR; Reddel RR
Cancer Res; 1999 Sep; 59(17):4175-9. PubMed ID: 10485449
[TBL] [Abstract][Full Text] [Related]
29. The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins.
Potts PR; Yu H
Nat Struct Mol Biol; 2007 Jul; 14(7):581-90. PubMed ID: 17589526
[TBL] [Abstract][Full Text] [Related]
30. Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies.
Jeyapalan JN; Mendez-Bermudez A; Zaffaroni N; Dubrova YE; Royle NJ
Int J Cancer; 2008 Jun; 122(11):2414-21. PubMed ID: 18311780
[TBL] [Abstract][Full Text] [Related]
31. The first molecular details of ALT in human tumor cells.
Muntoni A; Reddel RR
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R191-6. PubMed ID: 16244317
[TBL] [Abstract][Full Text] [Related]
32. Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients.
Sotillo-Piñeiro E; Sierrasesúmaga L; Patiñno-García A
Pediatr Res; 2004 Feb; 55(2):231-5. PubMed ID: 14630995
[TBL] [Abstract][Full Text] [Related]
33. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma.
Villa R; Daidone MG; Motta R; Venturini L; De Marco C; Vannelli A; Kusamura S; Baratti D; Deraco M; Costa A; Reddel RR; Zaffaroni N
Clin Cancer Res; 2008 Jul; 14(13):4134-40. PubMed ID: 18593991
[TBL] [Abstract][Full Text] [Related]
34. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma.
Chen YJ; Hakin-Smith V; Teo M; Xinarianos GE; Jellinek DA; Carroll T; McDowell D; MacFarlane MR; Boet R; Baguley BC; Braithwaite AW; Reddel RR; Royds JA
Cancer Res; 2006 Jul; 66(13):6473-6. PubMed ID: 16818615
[TBL] [Abstract][Full Text] [Related]
35. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression.
Costa A; Daidone MG; Daprai L; Villa R; Cantù S; Pilotti S; Mariani L; Gronchi A; Henson JD; Reddel RR; Zaffaroni N
Cancer Res; 2006 Sep; 66(17):8918-24. PubMed ID: 16951210
[TBL] [Abstract][Full Text] [Related]
36. Telomere-maintenance mechanisms in soft-tissue malignant fibrous histiocytomas.
Matsuo T; Shay JW; Wright WE; Hiyama E; Shimose S; Kubo T; Sugita T; Yasunaga Y; Ochi M
J Bone Joint Surg Am; 2009 Apr; 91(4):928-37. PubMed ID: 19339578
[TBL] [Abstract][Full Text] [Related]
37. Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex.
Jiang WQ; Zhong ZH; Henson JD; Neumann AA; Chang AC; Reddel RR
Mol Cell Biol; 2005 Apr; 25(7):2708-21. PubMed ID: 15767676
[TBL] [Abstract][Full Text] [Related]
38. Alternative lengthening of telomeres does exist in various canine sarcomas.
Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
[TBL] [Abstract][Full Text] [Related]
39. The alternative lengthening of telomeres pathway may operate in non-neoplastic human cells.
Slatter TL; Tan X; Yuen YC; Gunningham S; Ma SS; Daly E; Packer S; Devenish C; Royds JA; Hung NA
J Pathol; 2012 Feb; 226(3):509-18. PubMed ID: 22250043
[TBL] [Abstract][Full Text] [Related]
40. Telomere biology of pediatric cancer.
Tabori U; Dome JS
Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
